- Zacks Small Cap Research•2 months ago
By Grant Zeng, CFA OTC:GOVX On Jun 6, 2016, GeoVax (OTC:GOVX) announced the launch of a program to develop a therapeutic vaccine for treatment of chronic Hepatitis B infections (HBV). This announcement ...
- Zacks Small Cap Research•5 months ago
GeoVax (GOVX) has been busy in the past few months expanding its pipeline into new areas. In early February, 2016, GeoVax started a program to develop a vaccine for the prevention of Zika virus infections using its novel MVA-VLP vaccine platform. Recent outbreak of Zika virus in America makes the WHO to designate the Zika virus and its suspected complications in newborns an international public health emergency.
|52wk Range||0.05 - 0.14|
|Day's Range||0.08 - 0.08|
|Avg Vol (3m)||90,219|
As of 3:50 PM EDT. Market closed.